Company Filing History:
Years Active: 2022-2025
Title: Changsen Zhan: Innovator in Glycoside Compound Preparation
Introduction
Changsen Zhan is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of glycoside compounds, holding 2 patents that showcase his innovative methods and applications. His work is particularly relevant in the pharmaceutical industry, where his inventions aim to improve drug development processes.
Latest Patents
Changsen Zhan's latest patents include a preparation method of a glycoside compound. This method is characterized by short synthesis steps, high stereoselectivity and yield, simple production operation, low equipment requirements, and environmental protection, making it suitable for industrial mass production. Another notable patent is related to a glycoside compound represented by Formula III, which includes a preparation method, composition, use, and an intermediate. This glycoside compound can significantly increase the expression of VEGF-A mRNA and is effective in promoting angiogenesis. Such advancements provide a reliable guarantee for the development of drugs with pro-angiogenic activity, particularly for treating conditions like cerebral infarction, myocardial infarction, and ischemic microcirculatory disturbances of the lower limbs.
Career Highlights
Changsen Zhan is currently associated with Shanghai Hutchison Pharmaceuticals Limited, where he continues to innovate and contribute to the field of pharmaceuticals. His work has garnered attention for its potential impact on drug development and therapeutic applications.
Collaborations
Changsen Zhan has collaborated with notable colleagues, including Guoqiang Lin and Jiange Zhang, to further enhance the research and development of glycoside compounds.
Conclusion
Changsen Zhan's contributions to the field of glycoside compounds highlight his innovative spirit and dedication to advancing pharmaceutical science. His patents reflect a commitment to improving drug development processes and addressing critical health challenges.